Literature DB >> 35273707

Clinical characteristics and prognosis of patients with Castleman disease in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor.

Yibo Hua1, Chao Liang1, Jie Yang1, Luyang Wang2, Aimin Xu1, Lei Xi2, Shangqian Wang1, Zengjun Wang1.   

Abstract

OBJECTIVE: Castleman disease (CD) is a rare lymphoproliferative disorder with limited clinical research data. This study aimed to investigate the clinical manifestations, pathologic features, and prognostic factors of CD.
METHODS: The clinicopathological data of 54 patients with CD hospitalized in the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed. Univariate analysis and multivariate analysis were performed by Cox regression model to determine independent prognostic factors for patients' survival.
RESULTS: According to clinical classification, 30 cases (55.6%) had unicentric CD (UCD) and 24 cases (44.4%) had multicentric CD (MCD). Moreover, pathologic classification revealed 32 cases (59.3%) with hyaline vascular variant, 3 (5.6%) with mixed cellular variant, and 19 (35.2%) with plasmacytic variant. Patients with MCD commonly presented with clinical signs and symptoms, including fever, splenomegaly, and pleural effusion and/or ascites. Clinical complications, such as liver injury, anemia, and polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS) syndrome were more common in patients with MCD. Univariate analysis showed that the presence of paraneoplastic pemphigus (PNP) and the elevation of C-reactive protein were unfavorable prognosticators of survival in patients with CD. By multivariate analysis PNP was an independent prognostic factor in patients with CD.
CONCLUSIONS: This study provided a panoramic elaboration of CD cases and showed that the presence of PNP was an independent unfavorable factor. AJTR
Copyright © 2022.

Entities:  

Keywords:  Castleman disease; paraneoplastic pemphigus; prognostic factors; survival

Year:  2022        PMID: 35273707      PMCID: PMC8902542     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  28 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

Review 2.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

Review 3.  Surgery in Castleman's disease: a systematic review of 404 published cases.

Authors:  Nadia Talat; Ajay P Belgaumkar; Klaus-Martin Schulte
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

4.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

5.  Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia.

Authors:  G J Anhalt; S C Kim; J R Stanley; N J Korman; D A Jabs; M Kory; H Izumi; H Ratrie; D Mutasim; L Ariss-Abdo
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

6.  The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.

Authors:  T Powles; J Stebbing; A Bazeos; E Hatzimichael; S Mandalia; M Nelson; B Gazzard; M Bower
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

Review 7.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Stephen K Tyring; Martin Stuschke; Michael Roggendorf; Robert A Schwartz; Siegfried Seeber
Journal:  Lancet Infect Dis       Date:  2002-06       Impact factor: 25.071

8.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.

Authors:  Laurence Gérard; Alice Bérezné; Lionel Galicier; Véronique Meignin; Martine Obadia; Nathalie De Castro; Christine Jacomet; Renaud Verdon; Isabelle Madelaine-Chambrin; Emmanuelle Boulanger; Sylvie Chevret; Felix Agbalika; Eric Oksenhendler
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 9.  Diagnosis of Castleman Disease.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722

Review 10.  Idiopathic multicentric Castleman's disease: a systematic literature review.

Authors:  Amy Y Liu; Christopher S Nabel; Brian S Finkelman; Jason R Ruth; Razelle Kurzrock; Frits van Rhee; Vera P Krymskaya; Dermot Kelleher; Arthur H Rubenstein; David C Fajgenbaum
Journal:  Lancet Haematol       Date:  2016-03-17       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.